secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALNYLAM PHARMACEUTICALS, INC. (ALNY)
CIK:        0001178670
Form:       8-K
Filed at:   2025-10-03T23:59:59+00:00
Accession:  0001193125-25-230201
Event type: debt
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alnylam enters $500M revolving credit facility maturing 2030
------------------------------------------------------------

- New $500M Revolving Credit Facility includes $150M letter of credit sublimit; available for working capital and general corporate purposes.
- Interest rates: Term SOFR plus 1.50%–2.50% (based on Total Leverage Ratio); commitment fee 0.20%–0.35% on unused commitments.
- Financial covenants: Total Net Leverage Ratio ≤ 3.75:1.00 and Consolidated Interest Coverage Ratio ≥ 3.00:1.00, tested quarterly.
- Maturity September 30, 2030; springing maturity if outstanding Springing Maturity Debt exceeds $630M or 100% of EBITDA.
- Guaranteed by material domestic subsidiaries and secured by substantially all assets, subject to customary exceptions and release conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178670/000119312525230201/0001193125-25-230201-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178670/000119312525230201/d19737d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-230201

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer